VesiBeta 25 Tablet ER
Marketer
Cipla Ltd
Salt Composition
Mirabegron (25mg)
Overview VesiBeta 25 Tablet ER
VesiBeta 25 Extended-Release tablets alleviate overactive bladder symptoms such as urinary frequency, urgency, and incontinence. This medication promotes bladder muscle relaxation, enhancing urinary storage capacity. Always adhere to your physician's prescribed dosage and regimen. It may be taken with or without food; swallow the tablet whole, avoiding crushing or chewing. Discontinuing treatment prematurely may exacerbate symptoms; complete the prescribed course for optimal results. Potential side effects include constipation, headache, hypertension, rhinitis, urinary tract infection, tachycardia, and arthralgia. Report any persistent or bothersome side effects promptly to your doctor. Prior to commencing treatment, disclose all other medications and pre-existing conditions, including pregnancy or breastfeeding. Individuals with hepatic or renal impairment require careful monitoring and regular check-ups as directed by their doctor.
Primary Ingredients of VesiBeta 25 Tablet ER
The provided text is "undefined," therefore no rephrasing is possible.
Uses of VesiBeta 25 Tablet ER
Managing symptoms associated with overactive bladder
Major Benefits of VesiBeta 25 Tablet ER:
Administer VesiBeta 25 Tablet ER precisely as prescribed by your physician, adhering to both the dosage and treatment duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing. While consumption with or without food is acceptable, consistent daily timing is recommended for optimal results.
Common Side effects of VesiBeta 25 Tablet ER:
- Constipation
- Headache
- High blood pressure
- Nasal inflammation
- Urinary tract infection
- Fast heart rate
- Joint pain
How to use VesiBeta 25 Tablet ER:
Administer VesiBeta 25 Tablet ER precisely as prescribed by your physician, adhering to the specified dosage and treatment period. The tablet should be swallowed whole; avoid chewing, crushing, or breaking it. While consumption with or without food is acceptable, consistent daily timing is recommended for optimal results.
How VesiBeta 25 Tablet ER works:
VesiBeta 25 Extended-Release tablets utilize a beta-3 adrenergic agonist mechanism. This medication's action involves stimulating bladder beta-3 receptors, leading to detrusor muscle relaxation and, consequently, a reduction in urinary urgency, frequency, and incontinence.
SAFETY ADVICE
AlcoholCAUTION
Using VesiBeta 25 Tablet ER with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Extended-release VesiBeta 25mg tablets may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible risks prior to prescription. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Extended-release VesiBeta 25mg tablets are likely unsafe for breastfeeding mothers. Available evidence from human studies indicates potential transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by VesiBeta 25 ER tablets.
KidneyCAUTION
Extended-release VesiBeta 25 tablets require careful administration in individuals with advanced renal impairment. Dosage modification for VesiBeta 25 ER may be necessary. Physician consultation is advised.
LiverCAUTION
Patients with liver impairment should use VesiBeta 25 Extended-Release tablets cautiously, potentially requiring dosage modification. Consult your physician. VesiBeta 25 Extended-Release tablets are contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take VesiBeta 25 Tablet ER :
Should you forget a dose of VesiBeta 25 Tablet ER, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About VesiBeta 25 Tablet ER
| Label | Value |
|---|---|
| Chemical Classification | Anilide-based compound |
| Developing Habits | No. |
| Treatment Category | Urological Care |
| Actions | β3-Adrenergic receptor agonist (for bladder) |






